BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Multiple Myeloma

1 post

Multiple Myeloma is a type of blood cancer. The reason it’s called multiple myeloma is that the individual has a malignant plasma cell that spreads into more than one location in the body. It can affect bone marrow and also cause other symptoms such as fever, infections, kidney problems, trouble urinating and lung problems.

Multiple Myeloma can be treated with a combination of therapies. The most common treatments are chemotherapy, radiation therapy and stem cell transplant. In some cases, surgery may also be used.

The prognosis for multiple myeloma varies depending on the stage of the disease when it is diagnosed. However, many people with multiple myeloma can live for several years with treatment.

There is currently no cure for multiple myeloma, but research is ongoing to find new treatments and improve the prognosis for people with this disease.

If you or someone you know has been diagnosed with multiple myeloma, please talk to your doctor about the best treatment options.

Indapta Therapeutics Announces Data Demonstrating G-NK Cells Enhance Efficacy in Multiple Myeloma

Biotech NewsIndapta Therapeutics Announces Data Demonstrating G-NK Cells Enhance Efficacy in Multiple Myeloma

  • BioTech Health X
  • August 10, 2021
Indapta Therapeutics, Inc. today announced the publication of new preclinical data in Blood Advances demonstrating the company’s proprietary…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Niagen Bioscience (NAGE) Up 503% in 3 Years
  • Corvus Pharmaceuticals (CRVS) Net Loss Doubles to $8M in Q2 2025
  • Kestra Medical (KMTS) Surges on 52% Revenue Growth
  • GlucoTrack (GCTK) Posts $9.6M Cash Reserves
  • Adverum (ADVM) Could Soar 460% With $19.75 Target
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 13, 2025
    Niagen Bioscience (NAGE) Up 503% in 3 Years
    • September 13, 2025
    Corvus Pharmaceuticals (CRVS) Net Loss Doubles to $8M in Q2 2025
    • September 13, 2025
    Kestra Medical (KMTS) Surges on 52% Revenue Growth
    • September 12, 2025
    GlucoTrack (GCTK) Posts $9.6M Cash Reserves
    • September 7, 2025
    Adverum (ADVM) Could Soar 460% With $19.75 Target
Recent Posts
  • Spero Therapeutics (SPRO) Surges After 200% Stock Jump on Phase 3 Success
    • September 7, 2025
  • Tiziana (TLSA) Surges 143% in 2025
    • September 7, 2025
  • OKYO Pharma (OKYO) Surges on 75% Pain Reduction in Phase 2 Trial
    • September 7, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (379)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top